Resources for You
2014 Meeting Materials, Allergenic Products Advisory Committee
January 28, 2014
On January 28, 2014, the committee will meet in open session to discuss and make recommendations on the safety and efficacy of RAGWITEK, a short ragweed pollen allergen extract tablet for sublingual use, manufactured by Merck, indicated for immunotherapy for diagnosed ragweed pollen induced allergic rhinitis, with or without conjunctivitis.
- Announcement- Amendment
This amendment reflects a change in the conference room designation for the meeting.
- Briefing Document- Sponsor (PDF - 2.3MB)
Persons with disabilities having problems accessing the PDF may call 301-827-0314 for assistance.
- Briefing Document- FDA (PDF - 186KB)
- Draft Agenda
- Transcript (PDF - 208KB)
- Waivers for Conflicts of Interest